We could not reproduce results from Welch et al. [21] who reported TP53 mutation as a positive prognosis factor for response to decitabine without survival advantage, raising the question whether decitabine should be preferred to azacitidine in TP53 mutated AML patients. This evidence concerns the gene TP53 and acute myeloid leukemia.